Zobrazeno 1 - 10
of 98
pro vyhledávání: '"James C. Garbutt"'
Publikováno v:
NeuroImage: Clinical, Vol 32, Iss , Pp 102801- (2021)
A family history of alcoholism (FH) increases risk for alcohol use disorder (AUD), yet many at-risk individuals never develop alcohol use problems. FH is associated with intermediate levels of risk phenotypes, whereas distinct, compensatory brain cha
Externí odkaz:
https://doaj.org/article/bc6f6f0da37b441db09ea94215aa929f
Autor:
Renaud de Beaurepaire, Julia M. A. Sinclair, Mathis Heydtmann, Giovanni Addolorato, Henri-Jean Aubin, Esther M. Beraha, Fabio Caputo, Jonathan D. Chick, Patrick de La Selle, Nicolas Franchitto, James C. Garbutt, Paul S. Haber, Philippe Jaury, Anne R. Lingford-Hughes, Kirsten C. Morley, Christian A. Müller, Lynn Owens, Adam Pastor, Louise M. Paterson, Fanny Pélissier, Benjamin Rolland, Amanda Stafford, Andrew Thompson, Wim van den Brink, Lorenzo Leggio, Roberta Agabio
Publikováno v:
Frontiers in Psychiatry, Vol 9 (2019)
Alcohol use disorder (AUD) is a brain disorder associated with high rates of mortality and morbidity worldwide. Baclofen, a selective gamma-aminobutyric acid-B (GABA-B) receptor agonist, has emerged as a promising drug for AUD. The use of this drug r
Externí odkaz:
https://doaj.org/article/be518acbfc254740b3543c08429da6f2
Autor:
James C. Garbutt
Publikováno v:
Frontiers in Psychiatry, Vol 9 (2018)
Externí odkaz:
https://doaj.org/article/40ece902e62141aea8f5497c19dec6cb
Publikováno v:
Alcohol Alcohol
Aims We tested the hypothesis that high novelty seeking (NS—an externalizing trait), sweet-liking (SL—a phenotype that may reflect processing of hedonic stimuli) and initial insensitivity to the impairing effects of alcohol (SRE-A) act independen
Autor:
Robert Gallop, Alexei B. Kampov-Polevoy, Robyn Jordan, James C. Garbutt, Cort A. Pedersen, Melissa Stansbury, Laura Willing
Publikováno v:
Neuropsychopharmacology
Identification of new medications for alcohol use disorder (AUD) is important for improving treatment options. Baclofen, a GABABagonist, has been identified as a potential pharmacotherapy for AUD. In a 16-week double-blind, randomized, placebo-contro
Autor:
Todd E. Thiele, Cort A. Pedersen, T. Jordan Walter, Alexey B. Kampov-Polevoy, James C. Garbutt, Montserrat Navarro
Publikováno v:
Alcohol Alcohol
Aims The combination of bupropion and naltrexone has shown efficacy in reducing binge drinking in animal models. This study assessed the tolerability and potential utility of combined naltrexone and bupropion in reducing binge drinking in human subje
Autor:
James C. Garbutt, Kelly V. Stepanek, Allen Liles, Daniel E Jonas, John R. Stephens, Britta Starke, Carlton Moore
Publikováno v:
Journal of Hospital Medicine. 13:221-228
BACKGROUND Naltrexone trials have demonstrated improved outcomes for patients with alcohol use disorders. Hospital initiation of naltrexone has had limited study. OBJECTIVE To describe the implementation and impact of a process for counseling hospita
Autor:
James C. Garbutt, Daniel E Jonas
Publikováno v:
Medical Clinics of North America. 101:823-837
Unhealthy alcohol use is a leading causes of preventable death in the United States. Reducing unhealthy alcohol use should be a high priority for health care providers. Well-validated screening instruments are available, and behavioral counseling int
Autor:
Christina Makarushka, Susanna Naggie, Paolo Mannelli, Ashwin A. Patkar, Kelly A. Keefe, Andrew J. Muir, Terra Hodge, Michael W. Fried, Rae Jean Proeschold-Bell, John B. Wong, Donna M. Evon, Donna Niedzwiecki, James C. Garbutt, Julius M. Wilder, Jia Yao, Santanu K. Datta
Publikováno v:
Hepatology
Background and aims Hepatitis C virus (HCV) and alcohol use are patient risk factors for accelerated fibrosis progression, yet few randomized controlled trials have tested clinic-based alcohol interventions. Approach and results A total of 181 patien
Publikováno v:
NeuroImage : Clinical
NeuroImage: Clinical, Vol 32, Iss, Pp 102801-(2021)
NeuroImage: Clinical, Vol 32, Iss, Pp 102801-(2021)
A family history of alcoholism (FH) increases risk for alcohol use disorder (AUD), yet many at-risk individuals never develop alcohol use problems. FH is associated with intermediate levels of risk phenotypes, whereas distinct, compensatory brain cha